Stem Cell Therapeutics Closes $3.1 Million Financing

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.NEWSWIRE
SERVICES


Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT"), a life sciences company
developing stem cell-related technologies, announced today that it has closed
its previously announced prospectus offering of 12,315,000 units ("Units") at a
price of $0.25 per Unit for the aggregate gross proceeds of $3,078,750. 


Each Unit is comprised of one common share and one common share purchase warrant
(the "Warrant"). Each Warrant entitles the holder to purchase an additional
common share for $0.40 for a period of 60 months following the closing of the
offering. Euro Pacific Canada Inc. acted as the agent and Bloom Burton & Co., as
a selling firm for the offering.


The purpose of the offering is to provide the resources necessary to conclude
the acquisition of Trillium Therapeutics Inc. by SCT, announced February 4th,
2013, and to trigger a condition precedent to permit the exercise of the option
by SCT to acquire the license to the Tigecycline intellectual property from the
University Health Network/MaRS Innovation, Toronto, announced November 7th,
2012. The assets expected to be acquired and licensed will conclude the initial
step of SCT's published corporate objectives for advancing the Corporation's
interests. 


This news release shall not constitute an offer to sell nor the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics: 

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) develops stem cell-based
therapeutics through partnerships with research institutions and technology
transfer organizations. SCT's objectives include the sourcing and acquisition of
stem cell-related development opportunities, and securing capital for the
advancement of its licensed or acquired products. The Corporation's intended
corporate acquisitions and licensed acquisitions are positioning it principally
in the field of cancer stem cell therapeutic development. SCT is a member of the
20-member Centre for Commercialization of Regenerative Medicine consortium. For
more information, visit: www.stemcellthera.com.


Forward Looking Statements

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, uncertainties as to the timing and
closing of the proposed transaction with Trillium; the satisfaction of the
conditions precedent to the completion of the proposed transaction with
Trillium; the satisfaction of the conditions precedent to the exercise of the
option to acquire a license to certain technologies owned by University Health
Network; the exercise of the option to acquire a license to certain technologies
owned by University Health Network; the execution and delivery of a definitive
license agreement with University Health Network if SCT determines to exercise
the University Health Network option; the timing and closing of any concurrent
private placement; changing market conditions; the successful and timely
completion of pre-clinical and clinical studies; the establishment of corporate
alliances; the impact of competitive products and pricing; new product
development risks; uncertainties related to the regulatory approval process or
the ability to obtain drug product in sufficient quantity or at standards
acceptable to health regulatory authorities to complete clinical trials or to
meet commercial demand; and other risks detailed from time to time in SCT's
ongoing quarterly and annual reporting, including in the base shelf prospectus
dated March 1, 2011 and any prospectus supplement. Except as required by
applicable securities laws, SCT undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
[phone]
[e-mail]
www.StemCellThera.com